Browsing by Author "Dinleyici, Rümeysa"
Now showing items 1-4 of 4
-
Epidemiology of nosocomial candidemia, mortality, and antifungal resistance: 7-year experience in Turkey
Aydın, Selda; Derin, Okan; Şahin, Meyha; Dinleyici, Rümeysa; Yılmaz, Mesut; Ceylan, Bahadır; İstanbullu Tosun, Ayşe; Öztürk, Recep; Mert, Ali (National Institute of Health, 2022)Candidemia is an important clinical condition that prolongs hospital stays and increases morbidity, mortality, and hospital costs. The aim of this retrospective study was to evaluate the epidemiological and microbiological ... -
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase-producing enterobacter spp, citrobacter freundii, morganella morganii, providencia spp, or serratia marcescens: A pilot multicenter randomized controlled trial (MERINO-2)
Stewart, Adam G.; Paterson, David L.; Young, Barnaby; Lye, David C.; Davis, Joshua S.; Schneider, Kellie; Yılmaz, Mesut; Dinleyici, Rümeysa; Runnegar, Naomi; Henderson, Andrew; Archuleta, Sophia; Kalimuddin, Shirin; Forde, Brian M.; Chatfield, Mark D.; Bauer, Michelle J.; Lipman, Jeffrey; Harris-Brown, Tiffany; Harris, Patrick N. A. (Oxford University Press, 2021)Background: Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. ... -
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
Gemici, Aliihsan; Bilgen, Hülya; Erdoğan, Cem; Kansu, Abdullah; Olmuşçelik, Oktay; Beköz, Hüseyin Saffet; Dinleyici, Rümeysa; Mert, Ali; Sevindik, Ömür Gökmen (Tübitak Scientific & Technical Research Council Turkey, 2020)Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was ...
